Summit Therapeutics Inc.
SMMT
$16.18
$0.060.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 824.62% | 757.15% | 870.52% | 84.51% | 98.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 418.71% | 414.97% | 428.37% | 104.95% | 137.78% |
| Operating Income | -418.71% | -414.97% | -428.37% | -104.95% | -137.78% |
| Income Before Tax | -387.81% | -368.59% | -361.42% | -107.50% | 64.01% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -387.81% | -368.59% | -361.42% | -107.50% | 64.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -387.81% | -368.59% | -361.42% | -107.50% | 64.01% |
| EBIT | -418.71% | -414.97% | -428.37% | -104.95% | -137.78% |
| EBITDA | -418.86% | -415.17% | -428.70% | -105.11% | -138.21% |
| EPS Basic | -369.67% | -348.63% | -338.19% | -99.70% | 80.00% |
| Normalized Basic EPS | -404.19% | -385.73% | -382.53% | -86.97% | -78.39% |
| EPS Diluted | -350.86% | -341.11% | -335.38% | -110.98% | 79.10% |
| Normalized Diluted EPS | -404.19% | -385.73% | -382.53% | -86.97% | -78.39% |
| Average Basic Shares Outstanding | 4.07% | 4.39% | 4.87% | 4.01% | 16.15% |
| Average Diluted Shares Outstanding | 4.07% | 4.39% | 4.87% | 4.01% | 16.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |